<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00731900</url>
  </required_header>
  <id_info>
    <org_study_id>9561707009</org_study_id>
    <nct_id>NCT00731900</nct_id>
  </id_info>
  <brief_title>Pharmacogenetic Study for Topiramate-Induced Cognitive Dysfunction</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Taiwan University Hospital</source>
  <brief_summary>
    <textblock>
      Topiramate (TPM) is an antiepileptic drug with a unique mode of action that is often useful
      in patients refractory to other drugs. However its use is restricted by the high incidence of
      cognitive adverse drug reactions (ADRs) that are associated with TPM exposure. TPM has been
      shown to cause particular cognitive ADRs, characterized by verbal fluency, attention, working
      memory and language deficits, at a much higher rate than other antiepileptic drugs. There do
      not appear to be obvious differences between patients that do or do not experience cognitive
      ADRs when on TPM (e.g. age, sex, concomitant medications, diagnosis), which suggests a
      genetic contributor.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2007</start_date>
  <completion_date type="Anticipated">December 2009</completion_date>
  <primary_completion_date type="Anticipated">December 2009</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Cognitive Dysfunction</condition>
  <eligibility>
    <study_pop>
      <textblock>
        patients with epilepsy or patients with migraine treated by topiramate
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  adult (&gt;17 years old) patients with epilepsy or patients with migraine treated by
             topiramate

        Exclusion Criteria:

          -  allergy to topiramate

          -  abnormal liver or renal function
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>17 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Horng-Huei Liou, MD;PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Taiwan University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Horng-Huei Liou, MD;PhD</last_name>
    <phone>886-2-23123456</phone>
    <phone_ext>8325</phone_ext>
    <email>hhl@ntu.edu.tw</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Horng-Huei Liou, MD;PhD</last_name>
      <phone>886-2-23123456</phone>
      <phone_ext>8325</phone_ext>
      <email>hhl@ntu.edu.tw</email>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>August 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 7, 2008</study_first_submitted>
  <study_first_submitted_qc>August 8, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 11, 2008</study_first_posted>
  <last_update_submitted>August 8, 2008</last_update_submitted>
  <last_update_submitted_qc>August 8, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 11, 2008</last_update_posted>
  <responsible_party>
    <name_title>Hrong-Huei Liou, MD;PhD</name_title>
    <organization>National Taiwan University Hospital</organization>
  </responsible_party>
  <keyword>pharmacogenetic</keyword>
  <keyword>study</keyword>
  <keyword>Topirmate</keyword>
  <keyword>induced</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

